[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Arnold AA, Aboukameel A, Chen J, Yang D, Wang S, Al-Katib A, Mohammad RM: Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. Mol Cancer; 2008 Feb 14;7:20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model.
  • Elevated expression of anti-apoptotic Bcl-2 family proteins have been linked to a poor survival rate of patients with Follicular Lymphoma (FL).
  • This prompted us to evaluate a very potent non-peptidic Small-Molecule Inhibitor (SMI) targeting Bcl-2 family proteins, Apogossypolone (ApoG2) using follicular small cleaved cell lymphoma cell line (WSU-FSCCL) and cell isolated from lymphoma patients.
  • ApoG2 inhibited the growth of WSU-FSCCL significantly with a 50% growth inhibition of cells (IC50) of 109 nM and decreased cell number of fresh lymphoma cells.
  • In the WSU-FSCCL-SCID xenograft model, ApoG2 showed a significant anti-lymphoma effect, with %ILS of 84% in the intravenous and 63% in intraperitoneal treated mice.
  • These studies suggest that ApoG2 can be an effective therapeutic agent against FL.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, small cleaved-cell, follicular.
  • Genetic Alliance. consumer health - Follicular lymphoma 1.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Gossypol .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1984 Feb;44(2):768-71 [6581864.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1277-83 [11948143.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Apr;76(4):1019-24 [8473376.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Oct 1;70(1):62-7 [8221615.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1748-55 [7564520.001]
  • [Cites] Cancer Gene Ther. 1995 Sep;2(3):207-12 [8528964.001]
  • [Cites] Nature. 1996 May 23;381(6580):335-41 [8692274.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):27886-92 [9346936.001]
  • [Cites] Mol Hum Reprod. 1998 Dec;4(12):1099-109 [9872359.001]
  • [Cites] J Cell Biol. 1999 Jan 25;144(2):281-92 [9922454.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):441-6 [9989411.001]
  • [Cites] Br J Haematol. 2004 Dec;127(5):519-30 [15566355.001]
  • [Cites] Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):25-31 [15651174.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):344-54 [15531918.001]
  • [Cites] Oncology (Williston Park). 2005 Feb;19(2):213-28; discussion 228, 233-6, 239 [15770890.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Nursing. 2005 Jul;35(7):56-63; quiz 63-4 [15988223.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]
  • [Cites] Leuk Res. 2006 Mar;30(3):322-31 [16213584.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1419-21 [16645636.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4143-9 [16896003.001]
  • [Cites] J Med Chem. 2006 Oct 19;49(21):6139-42 [17034116.001]
  • [Cites] Leuk Res. 2006 Dec;30(12):1563-8 [16530831.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2006 Oct;28(8):533-91 [17136234.001]
  • [Cites] Chembiochem. 2007 Jan 2;8(1):113-21 [17139689.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):112-21 [17200714.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):621-9 [17255285.001]
  • [Cites] J Med Chem. 2007 Feb 22;50(4):641-62 [17256834.001]
  • [Cites] N Engl J Med. 2007 Feb 15;356(7):741-2 [17301308.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2226-35 [17404107.001]
  • [Cites] Cancer. 2007 May 15;109(10):2077-82 [17394190.001]
  • [Cites] Leuk Res. 2007 Jun;31(6):859-63 [17224180.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9303-7 [10734071.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(6):480-2 [1394805.001]
  • (PMID = 18275607.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109389; United States / NIGMS NIH HHS / GM / GM058905B; United States / NIGMS NIH HHS / GM / R25 GM058905; United States / NCI NIH HHS / CA / P30 CA022453; United States / NCI NIH HHS / CA / P30 CA22453-20
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Mcl1 protein, mouse; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspases; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ PMC2265299
  •  go-up   go-down


2. Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C: Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res; 2009 Jun 15;15(12):4038-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
  • PURPOSE: To investigate the activity of SAR3419, a novel humanized anti-CD19 antibody (huB4), conjugated to a cytotoxic maytansine derivative N(2)'-deacetyl-N(2)'-(4-mercapto-4-methyl-1-oxopentyl) maytansine, in preclinical xenograft models for non-Hodgkin's lymphoma.
  • EXPERIMENTAL DESIGN: Antitumor activity of SAR3419 was assessed as a single agent and in comparison with conventional therapies using a subcutaneous model for diffuse large B-cell lymphoma (WSU-DLCL2) and a systemic model for follicular small cleaved cell lymphoma (WSU-FSCCL) in mice with severe combined immune deficiency.
  • RESULTS: Our results showed that in these chemotherapy-resistant models, SAR3419 was more effective than CHOP (cyclophosphamide-Adriamycin-vincristine-prednisone) regimen or rituximab.
  • Only treatment with SAR3419 led to survival of the whole group of animals to the end of the experiment (150-155 days) in both models.
  • Treatment with rituximab resulted in antitumor activity in both models comparable with the low dose of SAR3419.
  • Necropsy and tissue staining in the WSU-FSCCL systemic model revealed that all deaths featured leptomeningeal lymphoma in the control and treated groups.
  • Interestingly, some of the animals that survived to the end of the experiment and seemed healthy at time of euthanasia did show microscopic evidence of lymphoma.
  • CONCLUSIONS: Overall, SAR3419 is a very active immunotoxin in preclinical models for human B-cell lymphoma and holds promise as a novel and well-tolerated therapy in B-cell non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Immunoconjugates / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Maytansine / analogs & derivatives. Maytansine / therapeutic use
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Antigens, CD19 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Line, Tumor. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunologic Factors / therapeutic use. Mice. Mice, SCID. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509168.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD19; 0 / Antineoplastic Agents, Phytogenic; 0 / Immunoconjugates; 0 / Immunologic Factors; 0 / N2'-deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine; 14083FR882 / Maytansine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


3. Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL: Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res; 2006 Dec 1;12(23):7174-9
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The humanized monoclonal antibody alemtuzumab (CAMPATH-1H) is specific for CD52 and is Food and Drug Administration - approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
  • The utility of CAMPATH in the treatment of other hematologic neoplasms has been explored; however, a comprehensive survey of CD52 expression among a broad spectrum of WHO-defined tumor types has not been completed.
  • RESULTS: The vast majority of low-grade B cell lymphoproliferative disorders (CLL/small lymphocytic leukemia, follicular lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, and mucosa-associated lymphoid tissue lymphomas) express CD52.
  • In addition, we found that the majority of precursor B cell acute lymphoblastic leukemia/lymphomas express this antigen.
  • In contrast, there is surprising heterogeneity in CD52 expression among more aggressive B cell lymphomas, with 25% of cases of diffuse large B cell lymphoma and Burkitt lymphoma demonstrating no detectable CD52.
  • In addition, the majority of neoplasms of the T cell lineage are negative for the antigen, including most cases of precursor T cell acute lymphoblastic leukemia/lymphoma, anaplastic large cell lymphoma, and peripheral T cell lymphoma, not otherwise specified.
  • Finally, the vast majority of cases of acute myeloid leukemia, Hodgkin lymphoma, and multiple myeloma are negative for CD52 expression.
  • CONCLUSION: In contrast with CLL, the variable expression of CD52 among other hematologic malignancies suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antigens, CD / biosynthesis. Antigens, Neoplasm / biosynthesis. Glycoproteins / biosynthesis. Leukemia, Myeloid. Lymphoma, B-Cell. Lymphoma, T-Cell. Lymphoproliferative Disorders
  • [MeSH-minor] Acute Disease. Antibodies, Monoclonal, Humanized. Humans. Immunohistochemistry. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145843.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  •  go-up   go-down


Advertisement
4. Bentz JS, Rowe LR, Anderson SR, Gupta PK, McGrath CM: Rapid detection of the t(11;14) translocation in mantle cell lymphoma by interphase fluorescence in situ hybridization on archival cytopathologic material. Cancer; 2004 Apr 25;102(2):124-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid detection of the t(11;14) translocation in mantle cell lymphoma by interphase fluorescence in situ hybridization on archival cytopathologic material.
  • BACKGROUND: The cytomorphologic diagnosis of mantle cell lymphoma (MCL) can be difficult and requires ancillary studies for accurate subclassification.
  • However, traditional cytogenetic studies on cytologic material can be both difficult technically and time consuming.
  • The authors evaluated the utility of interphase FISH for the rapid detection of t(11;14) in archival cytologic material.
  • Samples with tumor cell nuclei that showed at least one yellow fusion signal in addition one green signal (IgH) and one orange signal (CCND1) were interpreted as positive.
  • CONCLUSIONS: The cytomorphology of small-to-intermediate cell lymphomas, including MCL, follicular lymphoma, and marginal zone/mucosa-associated lymphoid tissue lymphoma, can show overlapping cytomorphologic features with one another as well as with reactive lymphoid proliferations.
  • In selected samples in which specific classification is not possible or when confirmation is required on a small sample size, molecular analysis and cytogenetics may be helpful in arriving at an unambiguous cytodiagnosis and subclassification.
  • Distinction of MCL from other lymphomas is important, because the clinical course is aggressive, and response to conventional chemotherapy is poor.
  • This study showed that the detection of t(11;14) by FISH can be performed rapidly and easily on archival cytologic material for the molecular diagnosis of MCL.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 14. In Situ Hybridization, Fluorescence. Lymphoma, Mantle-Cell / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15098257.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Asahi A, Okamoto S, Matsushita H, Hattori Y, Takayama N, Ikeda Y: [Follicular lymphoma in two brothers]. Rinsho Ketsueki; 2001 May;42(5):408-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Follicular lymphoma in two brothers].
  • Two brothers, whose parents had a history of exposure to atomic bomb radiation, developed non-Hodgkin's lymphoma.
  • The younger brother, a 48-year-old man, was diagnosed as having follicular small-cleaved cell lymphoma in October, 1996.
  • He had extranodal lymphoma involvement of the right kidney, bone marrow and skin, in addition to generalized lymphadenopathy.
  • He was treated with intermittent COP chemotherapy, and good control of the lymphoma was obtained.
  • The elder brother, aged 50 years, was diagnosed as having follicular mixed cell lymphoma in May, 1998.
  • He also had extranodal lymphoma involvement of the right parotid gland and bone marrow, as well as generalized lymphadenopathy.
  • After one course of CHOP chemotherapy, he developed paresis of the lower legs and was found to have a mass at the Th5-6 vertebrae by CT scan.
  • After four courses of CHOP chemotherapy followed by ESHAP chemotherapy and radiotherapy, he achieved complete remission, and has since been well.
  • Follicular lymphoma occurring among siblings is rare.
  • [MeSH-major] Lymphoma, Follicular / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Family Health. Humans. Male. Middle Aged. Nuclear Warfare. Prednisolone / administration & dosage. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11452461.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; COP protocol 2; VAP-cyclo protocol
  • [Number-of-references] 15
  •  go-up   go-down


6. Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, Takeuchi K, Watanabe C, Takahashi S, Ito Y, Hatake K: Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res; 2009 Apr 1;15(7):2523-30
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
  • PURPOSE: Rituximab is commonly incorporated into CD20-positive B-cell lymphoma therapy to improve response and prognosis.
  • With increasing use, resistance to rituximab is a continuing concern, but CD20 mutation as a cause of resistance has not previously been reported.
  • EXPERIMENTAL DESIGN: Freshly collected lymphoma cells from 50 patients with previously untreated or relapsed/resistant non-Hodgkin's B-cell lymphomas (diffuse large B cell, n = 22; follicular, n = 7; mucosa associated lymphoid tissue, n = 16; chronic lymphocytic leukemia, n = 2; small lymphocytic lymphoma, n = 1; lymphoplasmacytic, n = 1; mantle cell lymphoma, n = 1) were assessed for CD20 expression by flow cytometry, and CD20 gene sequencing was done on extracted DNA.
  • RESULTS: CD20 mutations were found in 11 (22.0%) of 50 patients and could be grouped as C-terminal deletion (8.0%), early termination (10.0%), and extracellular domain (2.0%) or transmembrane domain (2.0%) mutations.
  • The mean fluorescence intensity of CD20 on fresh lymphoma cells was significantly lower for the C-terminal deletion mutation [3.26; 95% confidence interval (95% CI), 0.09-6.89] compared with wild type (30.8; 95% CI, 22.4-39.2; P < 0.05).
  • In contrast, early termination mutations did not show significant differences in CD20 expression compared with wild type (19.5; 95% CI, 10.7-28.4; P > 0.05).
  • CONCLUSIONS: It is possible that C-terminal deletion mutations of CD20 may be related to relapse/resistance after rituximab therapy.
  • [MeSH-major] Antigens, CD20 / genetics. Drug Resistance, Neoplasm / genetics. Lymphoma, B-Cell / genetics. Sequence Deletion
  • [MeSH-minor] Amino Acid Sequence. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Humans. Molecular Sequence Data. Rituximab

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276251.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


7. Linck D, Lentini G, Tiemann M, Fauser AA, Parwaresch R, Basara N: Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma. Leuk Lymphoma; 2005 Feb;46(2):285-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma.
  • We describe successful treatment of a 38-year-old patient with composite lymphoma stage IV(A), who presented with multifocal enlarged lymph nodes.
  • The lymph node histology showed classic morphologic features of Hodgkin's disease, mixed cellularity subtype and follicular B-cell lymphoma.
  • Immunophenotypic analysis showed immunoreactivity for CD20, CD10 and Ki-67 in the malignant small cell population.
  • Both cell populations were bcl2-oncoprotein positive.
  • Restaging after chemotherapy showed radiological partial remission, but biopsy confirmed persisting follicular B-cell lymphoma without bone marrow infiltration and no evidence of Hodgkin's disease.
  • He was treated with monoclonal CD 20-antibody (Rituximab) 10 mg/kg weekly for eight consecutive weeks due to marked positivity of CD 20-antigen in follicular lymphoma cells.
  • This treatment was well tolerated and final staging showed complete remission of the composite lymphoma.
  • This patient continues to be in remission 28 months after the end of the treatment.
  • In conclusion, in the very rare case of composite lymphoma a combination of chemotherapy and subsequent immunotherapy might be considered as a promising therapeutic option.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology. Humans. Ki-67 Antigen. Leukemia, Lymphoid / drug therapy. Leukemia, Lymphoid / pathology. Male. Neprilysin. Remission Induction / methods. Rituximab

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621815.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Ki-67 Antigen; 4F4X42SYQ6 / Rituximab; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


8. Sakata K, Satoh M, Someya M, Asanuma H, Nagakura H, Oouchi A, Nakata K, Kogawa K, Koito K, Hareyama M, Himi T: Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer; 2004 Jan 15;100(2):356-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma.
  • BACKGROUND: Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of tumors that vary with regard to their biologic aggressiveness and clinical course.
  • In in vitro studies, matrix metalloproteinase 9 (MMP9) was reportedly expressed by human NHL cells and elevated levels of MMP9 have been observed in a subset of patients with high-grade NHL.
  • All but 1 patient had received radiation therapy and 92 patients also were treated with intensive combination chemotherapy.
  • RESULTS: Nearly all the patients with extranodal natural killer NK/T-cell lymphoma nasal type and anaplastic large cell lymphoma, T-cell/null cell type expressed MMP9.
  • In contrast, only a small fraction of the patients with mucosa-associated lymphoid tissue (MALT) lymphomas and follicular lymphomas expressed MMP9.
  • Approximately 50% of the diffuse large B-cell lymphoma (DLBCL) cases expressed MMP9.
  • The expression of MMP2 was noted in some of the patients with DLBCL and nasal NK/T-cell lymphoma.
  • Chemotherapy was associated with better overall survival in DLBCL patients who expressed MMP9.
  • Overall survival rates of T-cell/NK-cell lymphoma patients who expressed MMP9 appeared to be lower than that in those who did not express MMP9.
  • However, chemotherapy was not found to improve overall survival in patients who expressed MMP9.
  • CONCLUSIONS: MMP9 expression was observed in patients with aggressive NHL and was characterized by poor overall survival.
  • [MeSH-major] Lymphoma, Non-Hodgkin / enzymology. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism
  • [MeSH-minor] Adult. Female. Herpesvirus 4, Human / isolation & purification. Humans. Immunohistochemistry. In Situ Hybridization. Lymphoma, Large B-Cell, Diffuse / metabolism. Male. Middle Aged. Prognosis. RNA, Viral / analysis. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 14716772.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


9. Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs; 2003;63(8):803-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
  • Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukaemia (CLL).
  • While the optimal use of the drug in many clinical settings has yet to be clarified, two pivotal trials have established rituximab as a viable treatment option in patients with relapsed or refractory indolent NHL, and as a standard first-line treatment option when combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (the most common type of aggressive NHL).
  • The former was a noncomparative trial in relapsed indolent NHL (follicular and small lymphocytic subtypes) with clinical responses achieved in about half of patients treated with rituximab 375 mg/m(2) intravenously once weekly for 4 weeks, which was similar to some of the most encouraging results reported with traditional chemotherapeutic agents.
  • The latter was a randomised comparison of eight cycles of CHOP plus rituximab 375 mg/m(2) intravenously (one dose per cycle) versus CHOP alone in previously untreated elderly patients (60 to 80 years of age) with diffuse large B-cell lymphoma.
  • Treatment with rituximab is generally well tolerated, particularly in terms of adverse haematological effects and serious or opportunistic infections relative to standard chemotherapy.
  • CONCLUSIONS: Clinical trials with rituximab indicate that the drug has broad application to B-cell malignancies, although further clarification is needed to determine its optimal use in many of these clinical settings.
  • Importantly, rituximab in combination with CHOP chemotherapy has emerged as a new treatment standard for previously untreated diffuse large B-cell lymphoma, at least in elderly patients.
  • Compared with conventional chemotherapy, rituximab is associated with markedly reduced haematological events such as severe neutropenia, as well as associated infections.
  • Rituximab may be particularly suitable for elderly patients or those with poor performance status, and its tolerability profile facilitates its use in combination with cytotoxic drugs.
  • PHARMACODYNAMIC PROPERTIES: Rituximab is a mouse/human chimaeric IgG(1)-kappa monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes.
  • Although treatment with rituximab induces lymphopenia in most patients, typically lasting about 6 months, a full recovery of B lymphocytes in the peripheral blood is usually seen 9-12 months after therapy, as CD20 is not expressed on haematopoietic stem cells.
  • CD20 is, however, expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL) and to a lesser degree on B-cell chronic lymphocytic leukaemia (CLL) cells.
  • Although not fully elucidated, the cytotoxic effects of rituximab on CD20-positive malignant B cells appears to involve complement-dependent cytotoxicity, complement-dependent cellular cytotoxicity, antibody-dependent cellular cytotoxicity and induction of apoptosis.
  • In addition, in vitro data indicate that rituximab sensitises tumour cells to the effects of conventional chemotherapeutic drugs.
  • PHARMACOKINETIC PROPERTIES: Serum rituximab concentrations increased in proportion to dose across a wide range of single- and multiple-dose intravenous regimens in patients with B-cell NHL.
  • When administered at a dose of 375 mg/m(2) once weekly for 4 weeks in a pivotal trial in patients with relapsed or refractory indolent B-cell NHL (follicular or small lymphocytic subtypes), peak serum concentrations essentially doubled from the first (239.1 mg/L) to the fourth (460.7 mg/L) infusion, while elimination half-life (t(1/2)) increased from 76.3 to 205.8 hours (3.2 to 8.6 days).
  • The pharmacokinetic properties of rituximab are also characterised by wide inter-individual variability, and serum drug concentrations that are correlated with clinical response.
  • Although pharmacokinetic data are limited in patients with aggressive forms of NHL, such as diffuse large B-cell lymphoma, rituximab appears to have a similar pharmacokinetic profile in these patients to that in patients with indolent B-cell NHL.
  • The pharmacokinetics of rituximab are also reported to be similar whether the drug is administered with or without cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy.
  • THERAPEUTIC USE: A number of studies have demonstrated efficacy of intravenous rituximab in patients with various lymphoid malignancies of B-cell origin, including indolent (e.g. follicular lymphoma) and aggressive (e.g. diffuse large B-cell lymphoma) forms of NHL, and CLL, but the drug has not yet been approved for use in CLL, and approved indications in NHL vary between countries.
  • In the US, for example, rituximab is available for the treatment of patients with low-grade or follicular, relapsed or refractory, CD20-positive B-cell NHL.
  • In Europe, the drug has similar approval for relapsed or refractory follicular NHL as in the US, but has also been approved for use in combination with CHOP chemotherapy for the most common aggressive form of NHL (CD20-positive, diffuse large B-cell lymphoma).
  • In Japan, rituximab has been approved for indolent B-cell NHL and mantle cell lymphoma (an aggressive form of B-cell NHL), primarily on the basis of results of a Japanese phase II trial.
  • Indolent NHL: Results of several studies evaluating rituximab 375 mg/m(2) once weekly for 4 weeks in patients with indolent forms of B-cell NHL (primarily follicular and small lymphocytic lymphomas) showed objective response (OR) rates ranging from approximately 40-60% in those receiving the drug for relapsed or refractory indolent B-cell NHL, and slightly higher (50-70%) for those receiving rituximab as first-line therapy.
  • In a pivotal trial in 166 patients with relapsed or refractory low-grade or follicular B-cell NHL, intent-to-treat (ITT) analysis showed an OR rate of 48%, and a projected median time to progression of 13 months.
  • CHOP, fludarabine-containing regimens) or other drugs (e.g. interferon-alpha2a) in previously untreated patients with indolent forms of B-cell NHL (primarily follicular and small lymphocytic subtypes).
  • Follow-up data from a study in 40 patients with low-grade or follicular B-cell NHL treated with rituximab plus CHOP as first-line therapy showed that responses were durable with a progression-free survival and median duration of response >5 years.Bcl-2 gene rearrangement (t14;18) occurs in malignant cells in up to 85% of patients with follicular lymphoma, and minimal residual disease in peripheral blood and bone marrow can be monitored using polymerase chain reaction (PCR).
  • Aggressive NHL: Studies with rituximab as monotherapy in aggressive B-cell NHL, a potentially curable disorder, have generally been restricted to patients with relapsed or recurrent disease, since CHOP has traditionally been the standard first-line treatment regimen.
  • However, promising results from phase II monotherapy studies prompted further clinical investigation of rituximab in conjunction with chemotherapy.
  • Thus, most studies with rituximab in patients with aggressive forms of B-cell NHL have involved combination therapy, including a pivotal randomised trial comparing eight cycles of standard CHOP therapy plus rituximab 375 mg/m(2) (one dose per cycle) versus CHOP alone in 399 previously untreated elderly patients (60-80 years of age) with diffuse large B-cell lymphoma.
  • Other, smaller trials with rituximab in combination with CHOP or other chemotherapeutic regimens, either as first-line therapy or for patients with relapsed or refractory aggressive B-cell NHL, have also shown promising results in terms of clinical response rates.CLL: In relatively small trials (n < 40) conducted primarily in patients with relapsed or refractory B-cell CLL, rituximab monotherapy (various regimens) achieved OR rates of 23-45%, with median duration of response ranging from approximately 3-10 months. (ABSTRACT TRUNCATED)
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Drug Administration Schedule. Humans. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Oct 15;84(8):2457-66 [7522629.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Cancer Immunol Immunother. 2000 Mar;48(12):673-83 [10752475.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3266-74 [9336364.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):88-96 [10561023.001]
  • [Cites] Eur J Haematol. 2002 Jul;69(1):21-6 [12270058.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):477-81 [12688318.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):2-9 [28140087.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):709-23 [11297268.001]
  • [Cites] Ann Hematol. 2000 Jun;79(6):332-5 [10901614.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5A):2961-6 [11062708.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):30-35 [28140089.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):655-61 [10442187.001]
  • [Cites] Cell Immunol. 2000 Aug 25;204(1):55-63 [11006018.001]
  • [Cites] Semin Oncol. 2000 Dec;27(6 Suppl 12):53-61 [11226001.001]
  • [Cites] Blood. 1984 Jun;63(6):1424-33 [6609729.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1038-43 [11807010.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):81-8 [10848785.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3115-20 [12384407.001]
  • [Cites] Scand J Immunol. 2000 Jun;51(6):634-41 [10849376.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):79-87 [10561022.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2644-52 [10914705.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2217-24 [10498591.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):995-1001 [9818074.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):836-45 [11895917.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1326-31 [11520778.001]
  • [Cites] Blood. 2002 Jan 1;99(1):67-74 [11756154.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):105-112 [28140083.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1658-64 [12886256.001]
  • [Cites] Jpn J Cancer Res. 1998 Jul;89(7):748-56 [9738982.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1096-7 [11822361.001]
  • [Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):928-43 [12123339.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1392-8 [11222385.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1288-94 [11870171.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1991-2 [11565541.001]
  • [Cites] Ann Oncol. 2000 Apr;11(4):399-408 [10847457.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):374-5 [10811510.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1103-8 [15657404.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1229-30 [12414357.001]
  • [Cites] Eur J Health Econ. 2002;3(3):166-72 [15609141.001]
  • [Cites] Eur J Haematol. 2002 Sep;69(3):129-34 [12406005.001]
  • [Cites] Cancer J. 2002 Sep-Oct;8(5):371-6 [12416894.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3793-803 [10577851.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):70-74 [28140094.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2 Suppl 6):18-22 [12040530.001]
  • [Cites] Am J Hematol. 1992 Aug;40(4):259-63 [1380203.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Clin Lymphoma. 2000 Sep;1(2):146-51; discussion 152-3 [11707827.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):47-54 [10444162.001]
  • [Cites] J Immunol Methods. 1997 Mar 28;202(2):163-71 [9107305.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1735-44 [12200688.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]
  • [Cites] Blood Cells Mol Dis. 2000 Apr;26(2):133-43 [10753604.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Haematologica. 2002 Jul;87(7):719-29; discussion 729 [12091123.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2672; author reply 2673 [12360978.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1314-9 [11830481.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):697-714; discussion 714, 717, 721 [9597680.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):56-69 [28140093.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):791-5 [10071268.001]
  • [Cites] Drugs. 1999 Jul;58(1):79-88; discussion 89-90 [10439931.001]
  • [Cites] Bone Marrow Transplant. 2002 Feb;29 Suppl 1:S14-7 [11840156.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):109-14 [11249036.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):280-2 [11807154.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2771-7 [11675350.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3383-9 [11719378.001]
  • [Cites] Blood. 2003 May 1;101(9):3413-5 [12522009.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7170-6 [11156427.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):41-47 [28140091.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3800-7 [8204898.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1851-7 [10561225.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):75-80 [28140095.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):828-34 [12060117.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Clin Lymphoma. 2000 Dec;1(3):186-94; discussion 195-6 [11707828.001]
  • [Cites] Haematologica. 1998 Mar;83(3):209-16 [9573674.001]
  • [Cites] Ann Hematol. 2000 Sep;79(9):493-500 [11043420.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:123-6 [10707793.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]
  • [Cites] Blood. 2001 Jan 1;97(1):101-6 [11133748.001]
  • [Cites] Blood. 2002 Jun 15;99(12 ):4336-42 [12036859.001]
  • [Cites] Leuk Res. 2000 May;24(5):411-5 [10785263.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3449-57 [8507880.001]
  • [Cites] Bone Marrow Transplant. 1999 Sep;24(5):521-6 [10482937.001]
  • [Cites] J Clin Invest. 1981 Jan;67(1):134-40 [6969730.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Jun;12(3):177-86 [10851464.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):76-82 [10052709.001]
  • [Cites] Blood. 2002 Feb 1;99(3):856-62 [11806987.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):36-40 [28140090.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • (PMID = 12662126.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 177
  •  go-up   go-down


10. Lichtman SM, Petroni G, Schilsky RL, Johnson JL, Perri RT, Niedzwiecki D, Sklar J, Barcos M, Peterson BA: High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. Leuk Lymphoma; 2001 Nov-Dec;42(6):1255-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
  • The main objectives of this study were to determine the feasibility of administering high doses of cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) every 14-21 days to patients with follicular small cleaved cell lymphoma.
  • For each patient, the treatment was not considered feasible if fewer than four cycles of cyclophosphamide chemotherapy could be administered on schedule (i.e. at least every 29 days) or (1) hospitalization of the patient for longer than three days was necessary for neutropenic fever (38 degrees C) or bacteriologically documented infection in > 50% of the cycles, or (2) grade > or = 2 hemorrhage in association with thrombocytopenia of grade > or = 3 severity occurred in > 50% of the cycles or (3) non-hematologic toxicity (excluding nausea/vomiting and alopecia) of grade > or = 3 occurred in > 50% of cycles.
  • The goal was to have a treatment program feasible in 75% or more of the treated patients.
  • The secondary objectives were to determine the toxicities, the complete and partial response rates, and the time to treatment failure (TTF).
  • The trial also attempted to assess the effectiveness of this treatment program in eradicating Bcl-2 rearrangements by PCR, and to assess complete remission duration in relationship to PCR results in patients who respond to this chemotherapy program.
  • Patients were required to have histologically documented non-Hodgkin's lymphoma of the subtypes follicular, predominantly small cleaved cell (IWF-B) or follicular mixed, (IWF-C).
  • The median follow-up time is 5.0 years, with a range of 2.5-6.7 years.
  • The 1-year estimated probability of freedom from treatment failure was 50% and of survival at 1 year was 92%.
  • Post-treatment specimens were submitted for seven of the 13 patients.
  • Four of the seven converted to Bcl-2 negative following treatment.
  • Eight of 13 Bcl-2 positive patients (62%) had a clinical response to treatment.
  • This study demonstrates that repetitive doses of cyclophosphamide at 4.5 g/m2 every two weeks with rhG-CSF support can be administered to selected younger patients with advanced follicular lymphoma with morphologic involvement of the bone marrow with acceptable non-hematologic toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911406.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


11. Yaguchi T, Imaeda H, Kizaki M, Hosoe N, Suzuki H, Ogata H, Iwao Y, Kameyama K, Ikeda Y, Hibi T: Partial regression of duodenal lesions of intestinal follicular lymphoma after antibiotic treatment. Dig Endosc; 2010 Oct;22(4):316-8
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial regression of duodenal lesions of intestinal follicular lymphoma after antibiotic treatment.
  • A 51-year-old man was referred to our hospital because of duodenal lesions of lymphoma.
  • Biopsy specimens showed medium-sized centrocyte-like cells forming lymphoid follicles, and immunohistology showed positive staining for bcl-2 and CD10.
  • A small bowel series showed multiple granular lesions extending from the second portion of the duodenum to the proximal jejunum and the proximal ileum.
  • On the basis of these findings, the tumor was diagnosed as stage I follicular lymphoma (FL).
  • Although the patient was negative for Helicobacter pylori, he underwent antibiotic treatment.
  • The lesions improved 3 months after antibiotic treatment, but biopsy specimens showed residual lymphoma cells.
  • The patient therefore received combination chemotherapy with rituximab.
  • The partial regression of duodenal lesions of intestinal FL may be due to the effect of antibiotic treatment.
  • [MeSH-major] 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use. Amoxicillin / therapeutic use. Anti-Infective Agents / therapeutic use. Clarithromycin / therapeutic use. Duodenal Neoplasms / drug therapy. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Drug Therapy, Combination. Endoscopy, Gastrointestinal. Humans. Lansoprazole. Male. Middle Aged

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Digestive Endoscopy © 2010 Japan Gastroenterological Endoscopy Society.
  • (PMID = 21175486.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Infective Agents; 0K5C5T2QPG / Lansoprazole; 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin
  •  go-up   go-down


12. Shimazaki K, Ohshima K, Haraoka S, Suzumiya J, Nakamura N, Kikuchi M: Accessory cell tumour: a clinicopathological study of 16 aggressive tumours containing EBV-positive Hodgkin and Reed-Sternberg-like giant cells. Histopathology; 2002 Jan;40(1):12-21
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accessory cell tumour: a clinicopathological study of 16 aggressive tumours containing EBV-positive Hodgkin and Reed-Sternberg-like giant cells.
  • AIMS: Lymph nodes contain non-lymphoid accessory cells including follicular dendritic cells and interdigitating dendritic cells.
  • We present here the clinicopathological features of 16 cases of accessory cell tumour.
  • Tumour cells were composed of oval-to-spindle cells arranged in diffuse, vague storiform, fascicular and sometimes whorled patterns in a background of small lymphocytes.
  • Electron microscopic examination showed that many of the tumour cells had numerous interwoven long villous cell processes connected by occasional desmosomes.
  • Many tumours were very refractory to chemotherapy and radiation, with a few exceptions, and half of the cases classified initially as stage IV.
  • A short survival time, of 10 months or less, was observed in seven of 16 patients.
  • CONCLUSIONS: Our study identified more aggressive behaviour of accessory cell tumours.
  • Our results suggest that EBV may potentially induce activation of accessory cells to form Hodgkin and Reed-Sternberg-like giant cells, which correspond with poor prognosis.
  • [MeSH-major] Dendritic Cells, Follicular / pathology. Herpesvirus 4, Human / isolation & purification. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Reed-Sternberg Cells / pathology. Sarcoma / pathology
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Blotting, Southern. DNA, Neoplasm / analysis. Desmosomes / ultrastructure. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Male. Middle Aged. RNA, Viral / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11903594.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Viral
  •  go-up   go-down


13. Hatake K, Terui Y: [Rituximab resistance in B-cell lymphoma and its elimination]. Gan To Kagaku Ryoho; 2009 Apr;36(4):548-51
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rituximab resistance in B-cell lymphoma and its elimination].
  • Rituximab is commonly incorporated into CD20-positive B-cell lymphoma therapy to improve response and prognosis.
  • With increasing use, resistance to rituximab is a continuing concern, but CD20 mutation as a cause of resistance has not previously been reported.
  • Freshly collected lymphoma cells from 50 patients with previously untreated or relapsed/resistant non-Hodgkin's B-cell lymphomas(diffuse large B cell, n=22; follicular, n=7; mucosa associated lymphoid tissue, n=16; chronic lymphocytic leukemia, n=2; small lymphocytic lymphoma, n=1; lymphoplasmacytic, n =1; mantle cell lymphoma, n=1)were assessed for CD20 expression by flow cytometry, and CD20 gene sequencing was performed on extracted DNA.
  • The mean fluorescence intensity of CD20 on fresh lymphoma cells was significantly lower for the Cterminal deletion mutation(3.26; 95% CI: 0.09-6.89)compared with wild type(30.8; 95% CI: 22.4-39.2)(p<0.05).
  • In contrast, early termination mutations did not show significant differences in CD20 expression compared with wild type (19.5; 95% CI: 10.7-28.4)(p>0.05).
  • It is possible that C-terminal deletion mutations of CD20 may be related to relapse/resistance after rituximab therapy.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm / drug effects. Immunotherapy. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19381025.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


14. Day MJ, Henderson SM, Belshaw Z, Bacon NJ: An immunohistochemical investigation of 18 cases of feline nasal lymphoma. J Comp Pathol; 2004 Feb-Apr;130(2-3):152-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical investigation of 18 cases of feline nasal lymphoma.
  • This report details clinical, histopathological and immunohistochemical findings in 18 cats with chronic nasal disease diagnosed as nasal lymphoma.
  • Eight of the cats were female and 10 were male, with a median age of 10.5 years (range 7-14 years).
  • Nine cats received multi-agent chemotherapy or radiation therapy, or both, with survival times ranging from 14 to >541 days.
  • In 13 tissues, expression of class II molecules of the major histocompatibility complex and the myelomonocytic antigen MAC387 was also determined.
  • Twelve of the tumours were classified as diffuse large B-cell lymphomas, four as lymphoblastic B-cell lymphomas, and one as a follicular B-cell lymphoma.
  • One tumour was an anaplastic large cell neoplasm, in which the neoplastic cells expressed MHC class II alone in the absence of either lymphoid marker.
  • There was a variable infiltration of reactive small T lymphocytes into these tumours, and zones of necrosis within the tumour tissue were sometimes heavily infiltrated by MAC387+ phagocytic cells.
  • [MeSH-major] Cat Diseases / pathology. Lymphoma / pathology. Lymphoma / veterinary. Nose Neoplasms / pathology. Nose Neoplasms / veterinary
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cats. Female. Immunohistochemistry. Immunophenotyping. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15003473.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA: Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol; 2006 May 01;24(13):2105-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
  • PURPOSE: To determine the efficacy of bortezomib in patients with lymphoid malignancy, correlating clinical response with effect on plasma cytokines and in vitro activity in primary cultures.
  • Plasma tumor necrosis factor alpha (TNF-alpha) and interleukin-6 were measured before each treatment, and bortezomib activity was examined in patient samples grown in primary culture.
  • RESULTS: Fifty-one patients received a total of 193 cycles of treatment.
  • Twenty-four patients had mantle cell lymphoma (MCL), 13 had follicular lymphoma (FL), six had lymphoplasmacytic lymphoma, six had Hodgkin's disease (HD), and one each had diffuse large B-cell lymphoma and adult T-cell leukemia/lymphoma.
  • Patients were heavily pretreated with a median of four previous therapies.
  • Significant grade 3 to 4 toxicities were thrombocytopenia (n = 22), fatigue (n = 10), and peripheral neuropathy (n = 3).
  • Seven patients with MCL responded to treatment (one complete response, six partial responses [PRs]; overall response rate, 29%).
  • Two patients with FL achieved a late PR 3 months after discontinuing therapy.
  • A median reduction in plasma TNF-alpha of 98% was observed in six patients with MCL who responded to bortezomib compared with a reduction of 38% in six nonresponders (P = .07).
  • Response was associated with a reduction in plasma TNF-alpha and in vitro sensitivity in a small number of patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma / drug therapy. Pyrazines / therapeutic use. Tumor Necrosis Factor-alpha / analysis
  • [MeSH-minor] Adult. Aged. Bortezomib. Cell Line, Tumor. Cell Survival / drug effects. Cytokines / blood. Doxorubicin / pharmacology. Female. Humans. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16606971.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501974
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Cytokines; 0 / Pyrazines; 0 / Tumor Necrosis Factor-alpha; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin
  •  go-up   go-down


16. Portlock CS, Hamlin P, Noy A, Chey W, Gaydos CA, Palomba L, Schwartz I, Corcoran S, Rosenzweig L, Walker D, Papanicolaou G, Markowitz A: Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy. Ann Oncol; 2008 Feb;19(2):254-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy.
  • BACKGROUND: Eradication of Helicobacter pylori in gastric mucosa-associated lymphoid tumor can result in lymphoma remission.
  • We prospectively identified/treated infections in nonbulky, advanced stage indolent lymphoma (follicular; nonfollicular lymphoma) eligible for observation.
  • MATERIALS AND METHODS: Stool H. pylori, hepatitis C and Borrelia serologies, Borrelia and Chlamydia fixed tissue PCR, Chlamydia peripheral blood mononuclear cell PCR and hydrogen breath test for small bowel bacterial overgrowth (SBBO) were obtained.
  • Lymphoma responses to antimicrobial therapy: H. pylori [one complete response (CR), 24+ months; one transient near CR]; hepatitis C [two CRs, 18+ and 30+ months; one partial response (PR) but hepatitis C virus persistent]; SBBO (one PR, 30+ months).
  • Patients with associated infections, but without lymphoma CR, have required lymphoma treatment sooner than those without initial infections (treatment-free survival at 23.4 months median follow-up, 40.5% versus 74.7%, P = 0.01), indicating a different biology.
  • CONCLUSION: Infections are common in advanced stage indolent lymphoma (37.5% in our series).
  • Anecdotal lymphoma responses have been seen and three have been durable CRs (18 to 30+ months) with infection eradication alone.
  • The identification and treatment of associated infections may be a first step towards developing a lymphoma prevention strategy.


17. Ioannidis AS, Rai P, Mulholland B: Conjunctival lymphoid hyperplasia presenting with bilateral panuveitis. Am J Ophthalmol; 2005 Mar;139(3):566-8
Hazardous Substances Data Bank. FLUPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival lymphoid hyperplasia presenting with bilateral panuveitis.
  • PURPOSE: To report on a case of bilateral conjunctival lymphoid hyperplasia presenting with bilateral panuveitis in a female patient.
  • METHODS: In this case excisional biopsy indicated lymphoid tissue.
  • Immunohistochemistry showed a follicular architecture with appropriate zoning of B and T lymphocytes.
  • CONCLUSIONS: Ocular adnexal lymphoproliferative lesions consist of a spectrum of disease entities, including reactive lymphoid hyperplasia, atypical lymphoid hyperplasia, and lymphoma.
  • Furthermore, we advocate periodic follow-up examinations because of the small potential risk of developing ocular or systemic lymphoma in these patients.
  • [MeSH-minor] B-Lymphocytes / pathology. Drug Combinations. Female. Fluprednisolone / therapeutic use. Glucocorticoids / therapeutic use. Humans. Macular Edema / diagnosis. Macular Edema / drug therapy. Macular Edema / etiology. Middle Aged. Neomycin / therapeutic use. Polymyxin B / therapeutic use. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Panuveitis.
  • Hazardous Substances Data Bank. NEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767083.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Glucocorticoids; 1404-04-2 / Neomycin; 1404-26-8 / Polymyxin B; 78666-15-6 / Maxitrol; 9H05937G3X / Fluprednisolone
  •  go-up   go-down


18. Goteri G, Olivieri A, Ranaldi R, Lucesole M, Filosa A, Capretti R, Pieramici T, Leoni P, Rubini C, Fabris G, Lo Muzio L: Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome. Int J Immunopathol Pharmacol; 2006 Apr-Jun;19(2):421-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.
  • This study correlates bone marrow changes after Rituximab (RTX) treatment with the clinical characteristics and outcome of 26 patients with small B-cell lymphomas.
  • The percentage, phenotypic profile and clonality pattern of bone marrow lymphoid infiltrate were analysed before and after RTX treatment.
  • A favourable histology--follicular lymphoma (FL), hairy cell leukaemia (HCL) and marginal zone lymphoma (MZL)--was associated with a higher frequency of clinical CR and histological remission (HR), in comparison with mantle cell lymphoma (MCL), chronic lymphocytic leukaemia (CLL) and lymphoplasmacytic lymphoma (LPL).
  • 1) complete lymphoid cell disappearance (9 patients); or 2) nodular/interstitial T-cell infiltration (10 patients).
  • 1) persistence of CD20+ small lymphoid cells in 1 patient with MCL;.
  • 2) loss of CD20 antigen expression in 4 patients with CLL; or 3) persistence only of clusters of monotypic plasma cells in 2 patients with LPL.
  • In conclusion, bone marrow morphological and immunohistochemical analysis with a restricted panel of antibodies is useful to avoid 42% false positive and 85% false negative interpretations.
  • Persistence of monoclonality after RTX might have a role in evaluating the molecular pattern of CD20-negative clones that can emerge after RTX as a tumoral escape to therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Marrow / metabolism. Bone Marrow / pathology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cloning, Molecular. Female. Follow-Up Studies. Humans. Lymphocytes / immunology. Male. Middle Aged. Phenotype. Reverse Transcriptase Polymerase Chain Reaction. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831308.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


19. Alduaij A, Hansen K, Zhang C: Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report. Diagn Pathol; 2010;5:44
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report.
  • We report a rare case of primary lymphoma of fallopian tube in a 68-year-old woman who underwent total hysterectomy and bilateral salpingo-oophorectomy for endometrial carcinoma.
  • The specimen showed a well-differentiated endometrioid adenocarcinoma with superficial myometrial invasion.
  • The left fallopian tube revealed a 1 cm nodule that histologically showed diffuse lymphoid follicles consisting of small cleaved lymphocytes and occasional larger cells.
  • Polymerase chain reaction confirmed a monoclonal B-cell population.
  • The findings were consistent with a primary low grade follicular lymphoma of fallopian tube.
  • She did not receive chemotherapy and remained disease free for 13 months after surgery.
  • Our case suggests that primary lymphoma of fallopian tube may be associated with a favorable prognosis.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / pathology. Hysterectomy. Incidental Findings. Lymphoma, Follicular / pathology. Neoplasms, Multiple Primary. Ovariectomy
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Intraoperative Period. Translocation, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):384-6 [12217767.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1933-43 [6627208.001]
  • [Cites] Int J Gynecol Pathol. 2006 Jan;25(1):1-21 [16306779.001]
  • [Cites] Int J Gynecol Pathol. 1991;10(4):394-401 [1774110.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):736-8 [15581994.001]
  • [Cites] Pathol Annu. 1991;26 Pt 1:227-63 [2014141.001]
  • (PMID = 20584306.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2905343
  •  go-up   go-down


20. Cheson BD, Rummel MJ: Bendamustine: rebirth of an old drug. J Clin Oncol; 2009 Mar 20;27(9):1492-501
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bendamustine: rebirth of an old drug.
  • Bendamustine is a unique cytotoxic agent with structural similarities to alkylating agents and antimetabolites, but which is non-cross-resistant with alkylating agents and other drugs in vitro and in the clinic.
  • Early clinical studies conducted in the German Democratic Republic more than 30 years ago suggested promising activity in indolent non-Hodgkin's lymphoma (NHL).
  • Two North American trials reported responses in more than 70% of patients with chemotherapy- and rituximab-refractory disease, suggesting that bendamustine may be the most effective drug available for this patient population.
  • Response rates of 90% to 92%, with complete remission in 55% to 60%, have been reported in patients with follicular and mantle-cell lymphoma with the combination of bendamustine and rituximab.
  • Superiority over chlorambucil in previously untreated patients with chronic lymphocytic leukemia (CLL) led to its recent approval for this disease in the United States.
  • Bendamustine is approved in Germany for the treatment of patients with indolent NHL, CLL, and multiple myeloma.
  • Activity has also been noted in patients with breast cancer and small-cell lung cancer [corrected].
  • Questions related to the optimization of bendamustine therapy, including dose and schedule, role relative to other available agents, and management of toxicities, are being investigated.
  • However, the availability of bendamustine provides another effective treatment option for patients with lymphoid malignancies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Nitrogen Mustard Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Bendamustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2009 Jun 10;27(17):2892
  • (PMID = 19224851.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride
  • [Number-of-references] 66
  •  go-up   go-down


21. Colombo F, Viestenz A, Holbach LM: [Eyelid tumor as a recurrence of a gastric MALT-lymphoma]. Klin Monbl Augenheilkd; 2000 Aug;217(2):133-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Eyelid tumor as a recurrence of a gastric MALT-lymphoma].
  • [Transliterated title] Lidtumor als Rezidiv eines MALT-Lymphoms des Magens.
  • BACKGROUND: MALT Lymphoma of the conjunctiva, eyelid and orbit represents a primary manifestation of the disease in most of the cases.
  • CASE REPORT: A 58-year-old male presented with a tumor in the left inferior eyelid.
  • Histopathologically, a lymphoid infiltrate involved the eyelid in its full width, with reactive follicles surrounded by small cells with irregular nucleus.
  • Follicular colonization and lymphoepithelial lesions were detected.
  • The molecular genetic analysis disclosed a monoclonal B-cell proliferation.
  • The patient had a history of gastric MALT lymphoma treated 9 years ago and he had been otherwise in good health.
  • Since the eyelid tumor represented a recurrence of the disease, treatment consisted of systemic chemotherapy.
  • CONCLUSION: Ocular adnexal MALT-lymphomas may represent a recurrence of a distant primary MALT-lymphoma after a long disease-free period and, therefore, be an indication for systemic chemotherapy.
  • [MeSH-major] Eyelid Neoplasms / diagnosis. Eyelid Neoplasms / secondary. Lymphoma, B-Cell, Marginal Zone / diagnosis. Neoplasms, Second Primary / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Diagnosis, Differential. Disease-Free Survival. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11022670.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


22. Yang HB, Sheu BS, Wang JT, Lin ST, Wu JJ: Serological responses of FldA and small-molecular-weight proteins of Helicobacter pylori: correlation with the presence of the gastric MALT tissue. Helicobacter; 2004 Feb;9(1):81-6
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serological responses of FldA and small-molecular-weight proteins of Helicobacter pylori: correlation with the presence of the gastric MALT tissue.
  • PURPOSE: We tested whether the serological response to Flavodoxin-A (FldA) protein and anti-Helicobacter pylori immunoblots correlated to the degree of mucosaassociated lymphoid tissue (MALT) in the stomach.
  • METHODS: Eighty H. pyloni-infected patients with different degrees of MALT in the stomach were investigated with serum sampling and endoscopy on enrolment, the 2nd and the 12th months after anti-H. pylori therapy.
  • Regression of follicular gastritis was assessed by histology.
  • RESULTS: Patients with dense lymphoid follicles had higher prevalence rates of anti-FldA protein, 19.5, 26.5, and 30 KDa antibodies of H. pylori (p < .05).
  • Histologic downgrade of MALT was observed in 25% (10/40) of patients in the 2nd month and in 60% (23/38) in the 12th month after H. pylori therapy.
  • After H. pylori eradication, the patients with MALT and dense lymphoid follicles had significantly negative seroconversions of 19.5, 26.5, 30, and 35 KDa antibodies (p < .05), but not of CagA and FldA.
  • CONCLUSION: Patients with gastric MALT and dense lymphoid follicles had different anti-H. pylori serological responses to those with scanty or an absence of lymphoid follicles.
  • [MeSH-major] Antibodies, Bacterial / blood. Bacterial Proteins / immunology. Flavoproteins / immunology. Gastric Mucosa / pathology. Helicobacter Infections / drug therapy. Helicobacter Infections / immunology. Helicobacter pylori / immunology. Lymphoid Tissue / pathology. Lymphoma, B-Cell, Marginal Zone / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15156908.001).
  • [ISSN] 1083-4389
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Flavoproteins; 0 / FldA protein, Bacteria; 0 / cagA protein, Helicobacter pylori
  •  go-up   go-down


23. Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, Rodriguez MA, Ha CS, Smith TL, Ayala A, Hess M, Cox JD, Cabanillas F, McLaughlin P: Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol; 2003 Jun 1;21(11):2115-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
  • PURPOSE: Standard therapy for patients with stage I-II indolent lymphoma has been involved-field radiation therapy (IF-XRT), which achieves 10-year disease-free survival in 40% to 50% of patients, with many of these patients cured.
  • We investigated the potential for combined-modality therapy to increase the disease-free survival for such patients.
  • PATIENTS AND METHODS: A total of 102 eligible patients with stage I-II low grade lymphoma (International Working Formulation criteria) were enrolled from 1984 to 1992.
  • Treatment comprised 10 cycles of risk-adapted chemotherapy (cyclophosphamide, vincristine, prednisone, bleomycin [COP-Bleo], and with doxorubicin added for some [CHOP-Bleo]) and 30 to 40 Gy IF-XRT.
  • RESULTS: The patients' median age was 56 years (range, 28 to 77), with follicular histology in 83%, bulky disease (>/= 5 cm) in 24%, and stage II in 52%.
  • There were no treatment-related deaths and 99% of patients attained complete remission.
  • With a median follow-up of 10 years, the 10-year time to treatment failure and overall survival were 76% and 82%, respectively.
  • For patients with follicular lymphoma, these figures were 72% and 80%, respectively.
  • The only factor associated with treatment failure, for follicular lymphoma patients, was stage-modified International Prognostic Factors Index score (P =.02).
  • None of 17 patients with diffuse small lymphocytic or mucosa-associated lymphoid tissue histology have relapsed.
  • CONCLUSION: With prolonged follow-up, combined-modality therapy with risk-adapted COP-/CHOP-Bleo and IF radiation has attained higher rates of disease control and survival than previously reported with IF-XRT alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / mortality. Lymphoma, Follicular / pathology. Lymphoma, Follicular / radiotherapy. Male. Middle Aged. Radiotherapy / methods. Survival Rate

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12775737.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP-B protocol
  • [Number-of-references] 60
  •  go-up   go-down


24. Niitsu N, Nakamine H, Hayama M, Unno Y, Nakamura S, Horie R, Iwabuchi K, Nakamura N, Miura I, Higashihara M: Ovarian follicular lymphoma: a case report and review of the literature. Ann Hematol; 2002 Nov;81(11):654-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian follicular lymphoma: a case report and review of the literature.
  • Primary ovarian lymphoma is extremely rare, and such a case is reported here.
  • Pelvic CT and MRI showed a right ovarian tumor with a diameter of 7 cm and an irregular border.
  • With the diagnosis of a right ovarian tumor, the patient underwent a simple hysterectomy and bilateral salpingo-oophorectomy.
  • Microscopic examination of the right ovarian tumor revealed vaguely nodular growth of small lymphoid cells.
  • They were CD10+, Bcl-2+, Cyclin D1- and CD21-, although CD21+ follicular dendritic cell clusters were present as a background component in each vague nodule.
  • These findings led us to characterize the lesion as follicular lymphoma, grade 1.
  • The patient was free of detectable disease 9 months after initiation of post-surgical chemotherapy.
  • Since the prognosis for primary ovarian lymphoma is relatively favorable in many cases, it is important to establish therapeutic methods for the cure of this disease using chemotherapy and radiotherapy without radical surgery.
  • [MeSH-major] Lymphoma, Follicular / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Cytogenetic Analysis. Dendritic Cells / pathology. Female. Genes, Immunoglobulin. Humans. Hysterectomy. Middle Aged. Ovariectomy. Remission Induction / methods. Translocation, Genetic


25. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood; 2010 Apr 01;115(13):2578-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
  • Certain malignant B cells rely on B-cell receptor (BCR)-mediated survival signals.
  • In in vivo analyses of B-cell lymphoma cell lines and primary tumors, Syk inhibition induces apoptosis.
  • These data prompted a phase 1/2 clinical trial of fostamatinib disodium, the first clinically available oral Syk inhibitor, in patients with recurrent B-cell non-Hodgkin lymphoma (B-NHL).
  • (1) diffuse large B-cell lymphoma (DLBCL), (2) follicular lymphoma (FL), and (3) other NHL, including mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), mucosa-associated lymphoid tissue lymphoma, lymphoplasmacytic lymphomas, and small lymphocytic leukemia/chronic lymphocytic leukemia (SLL/CLL).
  • Objective response rates were 22% (5 of 23) for DLBCL, 10% (2 of 21) for FL, 55% (6 of 11) for SLL/CLL, and 11% (1/9) for MCL.
  • Disrupting BCR-induced signaling by inhibiting Syk represents a novel and active therapeutic approach for NHL and SLL/CLL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Oxazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Diarrhea / chemically induced. Disease-Free Survival. Female. Hematologic Diseases / chemically induced. Humans. Hypertension / chemically induced. Male. Middle Aged. Salvage Therapy. Syk Kinase. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Feb 15;356(7):741-2 [17301308.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2093-101 [17051243.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Jun 15;221(3):268-77 [17490694.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2230-7 [18006696.001]
  • [Cites] Blood. 2008 Aug 1;112(3):782-92 [18487510.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]
  • [Cites] Arthritis Rheum. 2008 Nov;58(11):3309-18 [18975322.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):549-62 [19017179.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2009 Feb;85(2):130-6 [19107952.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2508-16 [18981293.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3050-8 [19074730.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3154-60 [19096013.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6153-60 [19369227.001]
  • [Cites] Blood. 2009 Jul 16;114(3):638-46 [19387007.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1029-37 [19491390.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3822-9 [19581539.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4156-62 [16912221.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Immunol Today. 2000 Mar;21(3):148-54 [10689303.001]
  • [Cites] J Immunol. 2000 Aug 1;165(3):1300-6 [10903730.001]
  • [Cites] Science. 2002 May 31;296(5573):1641-2 [12040177.001]
  • [Cites] J Allergy Clin Immunol. 2002 Sep;110(3):366-73 [12209081.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1057-69 [12453414.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Cell. 2004 Jun 11;117(6):787-800 [15186779.001]
  • [Cites] Mol Cell. 2004 Jun 18;14(6):696-7 [15200948.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1073-83 [9323135.001]
  • [Cites] Curr Opin Immunol. 1999 Apr;11(2):143-51 [10322153.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:329-34 [16304399.001]
  • [Cites] Br J Haematol. 2006 Feb;132(3):303-16 [16409295.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):283-94 [16557260.001]
  • [Cites] J Immunol. 2006 May 15;176(10):5715-9 [16670274.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3135-42 [16835385.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3428-33 [16888096.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008 [16946104.001]
  • [CommentIn] Blood. 2010 Apr 1;115(13):2561-2 [20360472.001]
  • (PMID = 19965662.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00446095
  • [Grant] United States / NCI NIH HHS / CA / P50 CA130805; United States / NCI NIH HHS / CA / CA-130805
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / Oxazines; 0 / Protein Kinase Inhibitors; 0 / Pyridines; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / SYK protein, human; EC 2.7.10.2 / Syk Kinase; SQ8A3S5101 / fostamatinib
  • [Other-IDs] NLM/ PMC2852362
  •  go-up   go-down


26. Yi XH, Zhou XY, Zhang TM, Zhou CC, Su B, Zhang Y: [The value of detection of gene rearrangement of immunoglobulin heavy chain and immunohistochemistry in pulmonary mucosa-associated lymphoid tissue type lymphoma]. Zhonghua Jie He He Hu Xi Za Zhi; 2005 Oct;28(10):704-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of detection of gene rearrangement of immunoglobulin heavy chain and immunohistochemistry in pulmonary mucosa-associated lymphoid tissue type lymphoma].
  • OBJECTIVE: To investigate the features of gene rearrangement of immunoglobulin heavy chain (IgH) and immunophenotypes of pulmonary mucosa-associated lymphoid tissue type lymphoma (MALTLoma).
  • METHODS: The clinical and pathological data of 12 cases with pulmonary MALTLoma and follow-up information were retrospectively reviewed, and the paraffin-embedded samples were examined with immunohistochemistry staining (12 cases) and semi-nested polymerase chain reaction (PCR) for IgH and T-cell receptor gamma (TCRgamma) gene rearrangement (7 cases).
  • Histopathologically, the tumors were composed of a spectrum of cell types that included mainly centrocyte-like cells and small lymphocytes.
  • Lymphoepithelial lesions were identified in 12 cases, reactive colliculus lymphaticus in 11 cases, follicular colonization in 10 cases, vascular infiltration in 9 cases, and pleura involvement in 4 cases.
  • All cases showed immunoreactivity for B-cell correlative markers.
  • The detection of TCRgamma1 and TCRgamma2 was negative in 7 cases.
  • Chemotherapy alone was administered in 3 patients, surgery alone was performed in 8 patients, and chemotherapy after operation was carried out in 6 patients.
  • Eight of them were alive and stable, one experienced relapse and two died of the disease within 11 years and 12 years after diagnosis respectively.
  • PCR detection of IgH gene rearrangement would be helpful in differential diagnosis from benign lymphoplasia of the lung.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / genetics
  • [MeSH-minor] Aged. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16255957.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


27. Tu PH, Giannini C, Judkins AR, Schwalb JM, Burack R, O'Neill BP, Yachnis AT, Burger PC, Scheithauer BW, Perry A: Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol; 2005 Aug 20;23(24):5718-27
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma.
  • PURPOSE: Although rare overall, marginal zone B-cell lymphoma (MZBCL) is the most common primary low-grade CNS lymphoma reported in the literature.
  • Ten patients with 1 to 7.6 years of follow-up after diagnosis showed no evidence of disease after radiation and/or chemotherapy.
  • Like MZBCLs outside of the CNS, they consisted of CD20+, CD3- small B lymphocytes with varying degrees of plasmacytic differentiation and predominantly kappa light-chain restriction (78%).
  • Lymphoid follicles with follicular colonization were seen in three patients and deposition of amyloid was noted in samples from two patients, one of which was tumefactive.
  • CONCLUSION: Our data suggest that intracranial MZBCL is an indolent primary CNS lymphoma that typically presents as a meningioma-like dural-based mass.
  • Trisomy 3, but not MALT1 or IgH translocation, is a common genetic abnormality that may contribute to the pathogenesis of this CNS lymphoma.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009945.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Murtha AD, Rupnow BA, Hansosn J, Knox SJ, Hoppe R: Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University. Int J Radiat Oncol Biol Phys; 2001 Jan 1;49(1):3-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University.
  • PURPOSE: To report the long-term survival and late toxicity data of Stage III follicular lymphoma patients treated with primary radiotherapy.
  • METHODS AND MATERIALS: Sixty-six patients with Stage III follicular small cleaved (FSC) or follicular mixed (FM) non-Hodgkin's lymphoma were treated with total lymphoid irradiation (61 patients) or whole body irradiation (5 patients) as their primary treatment modality from 1963 to 1982 at Stanford University.
  • Adjuvant chemotherapy was given to 13 patients.
  • RESULTS: Median follow-up was 9.5 years with a range of 0.5-24.3 years.
  • Few initial relapses or lymphoma-related deaths were seen beyond the first decade of follow-up.
  • CONCLUSION: The long-term survival data for Stage III FSC or FM non-Hodgkin's lymphoma treated with primary radiotherapy are at least comparable and possibly better than results achieved with other therapeutic approaches.
  • Whether these results are superior to an initial approach of deferred therapy until clinically indicated is currently unknown.
  • [MeSH-major] Lymphoma, Follicular / radiotherapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Cohort Studies. Female. Follow-Up Studies. Humans. Lymphatic Irradiation. Male. Middle Aged. Neoplasm Staging. Recurrence. Survival Analysis. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):1-2 [11163491.001]
  • [ErratumIn] Int J Radiat Oncol Biol Phys 2001 May 1;50(1):285
  • (PMID = 11163492.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Armitage JO, Tobinai K, Hoelzer D, Rummel MJ: Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. Int J Hematol; 2004 May;79(4):311-21
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.
  • The term indolent in describing a non-Hodgkin's lymphoma (NHL) generally refers to a group of B-cell NHLs composed of predominantly small cells that make up several categories, including follicular lymphoma, small lymphocytic lymphoma, and lymphoma of mucosa-associated lymphoid tissue.
  • Most patients with follicular lymphoma respond to therapy, and the average survival time in large series is approximately 10 years.
  • Patients who achieve a complete remission with initial treatment have an approximately 25% chance of remaining free of disease for 10 years.
  • However, this means that more than 80% of patients will require salvage therapy.
  • It is cytotoxic to both proliferating and resting lymphocytes, making it an attractive agent for the treatment of indolent NHL.
  • In this review article, we summarize the current treatment approaches for indolent NHL and the results of cladribine monotherapy studies in Japan and cladribine studies in Germany that have focused on a combination therapy with mitoxantrone.
  • Cladribine is highly effective as a single agent and in combination with mitoxantrone in the treatment of indolent NHL, and its availability broadens the range of therapeutic options for indolent NHL.
  • [MeSH-major] Cladribine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Follicular / drug therapy. Treatment Outcome

  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):88-96 [10561023.001]
  • [Cites] Leuk Lymphoma. 1999 Sep;35(1-2):129-38 [10512170.001]
  • [Cites] Blood. 1992 Aug 1;80(3):587-92 [1353380.001]
  • [Cites] Leuk Lymphoma. 2000 Feb;36(5-6):559-67 [10784401.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Nov;77(11):6865-9 [6256765.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):445-50 [9053464.001]
  • [Cites] Ann Oncol. 1995 Jan;6(1):49-52 [7710983.001]
  • [Cites] Blood Rev. 2000 Mar;14(1):1-13 [10805257.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):721-6 [9739437.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):570-4 [7884417.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Dec;74(12):5677-81 [202960.001]
  • [Cites] Leuk Lymphoma. 1999 Jan;32(3-4):359-63 [10037034.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Jpn J Clin Oncol. 1993 Aug;23(4):250-7 [8411739.001]
  • [Cites] Blood. 1996 Feb 1;87(3):906-11 [8562961.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2203-9 [1358262.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1821 [1357112.001]
  • [Cites] N Engl J Med. 1990 Apr 19;322(16):1117-21 [1969613.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):512-7 [12841391.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1219-27 [11728680.001]
  • [Cites] J Clin Invest. 1985 Feb;75(2):377-83 [2579098.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Lancet. 1992 Oct 17;340(8825):952-6 [1357355.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):891-6 [12610190.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1514-8 [1357107.001]
  • [Cites] Clin Cancer Res. 1995 Apr;1(4):385-90 [9815995.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):637-45 [10442184.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]
  • [Cites] Blood. 1994 Aug 1;84(3):733-8 [7913841.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Apr;10(4):489-97 [6725039.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1316-23 [10715303.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1282-90 [8648385.001]
  • [Cites] Lancet. 2002 Aug 17;360(9332):547-8 [12241663.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3325-33 [10552941.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2216-28 [7931492.001]
  • [Cites] J Clin Oncol. 1986 Oct;4(10):1470-80 [3531422.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2139-44 [8683247.001]
  • [Cites] Lancet. 1997 Apr 19;349(9059):1137-41 [9113013.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1746-51 [12721250.001]
  • [Cites] J Clin Oncol. 2001 Oct 1;19(19):3918-28 [11579112.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):989-95 [7707128.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):39-40 [11197361.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):52-60 [8996124.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):679-89 [8097528.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):371-7 [1346801.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2747-53 [12860954.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Jpn J Clin Oncol. 1997 Jun;27(3):146-53 [9255268.001]
  • [Cites] Br J Cancer. 1993 Jan;67(1):139-43 [8094003.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):850-8 [9508165.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):788-92 [7908690.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1803-10 [9164188.001]
  • [Cites] Blood. 2001 Jan 15;97(2):404-9 [11154216.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1710-6 [7655003.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(6):640-5 [11128815.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • (PMID = 15218957.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; BZ114NVM5P / Mitoxantrone
  • [Number-of-references] 74
  •  go-up   go-down






Advertisement